Genmab
ISIN: DK0010272202 | Ticker: GMAB | LEI: 529900MTJPDPE4MHJ122
Country: Denmark
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Our headquarter is in Copenhagen, Denmark with sites in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan.
We are the creators of three marketed products* and have a broad clinical and pre-clinical product pipeline. Genmab's technology consists of validated and proprietary next-generation antibody platforms - DuoBody® for generation of bispecific antibodies; HexaBody®, which creates effector-function enhanced antibodies; HexElect®, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency; and DuoHexaBody®, which enhances the potential potency of bispecific antibodies through hexamerization.
1999
HeadquartersKalvebod Brygge 43, 1560 Copenhagen – Denmark
| Line item in (dkk) | 01.01.2019 | 01.01.2020 | 01.01.2021 | 01.07.2021 | 01.10.2021 | 01.01.2022 | 01.04.2022 | 01.07.2022 | 01.10.2022 | 01.01.2023 | 01.04.2023 | 01.07.2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | N/A | N/A | 21,143,000,000.00 | N/A | N/A | 24,627,000,000.00 | N/A | 27,476,000,000.00 | 30,686,000,000.00 | 30,278,000,000.00 | N/A | 31,978,000,000.00 |
| Noncurrent Assets | N/A | N/A | 2,352,000,000.00 | N/A | N/A | 1,891,000,000.00 | N/A | 1,985,000,000.00 | 1,947,000,000.00 | 1,901,000,000.00 | N/A | 2,229,000,000.00 |
| Property Plant And Equipment | N/A | N/A | 453,000,000.00 | N/A | N/A | 621,000,000.00 | N/A | 684,000,000.00 | 741,000,000.00 | 799,000,000.00 | N/A | 908,000,000.00 |
| Intangible Assets Other Than Goodwill | N/A | N/A | 338,000,000.00 | N/A | N/A | 254,000,000.00 | N/A | 216,000,000.00 | 200,000,000.00 | 146,000,000.00 | N/A | 129,000,000.00 |
| Noncurrent Receivables | N/A | N/A | 20,000,000.00 | N/A | N/A | 27,000,000.00 | N/A | 66,000,000.00 | 39,000,000.00 | 48,000,000.00 | N/A | 31,000,000.00 |
| Deferred Tax Assets | N/A | N/A | 177,000,000.00 | N/A | N/A | 264,000,000.00 | N/A | 264,000,000.00 | 264,000,000.00 | 252,000,000.00 | N/A | 252,000,000.00 |
| Noncurrent Investments Other Than Investments Accounted For Using Equity Method | N/A | N/A | 1,081,000,000.00 | N/A | N/A | 371,000,000.00 | N/A | 201,000,000.00 | 155,000,000.00 | 133,000,000.00 | 140,000,000.00 | 183,000,000.00 |
| Current Assets | N/A | N/A | 18,791,000,000.00 | N/A | N/A | 22,736,000,000.00 | N/A | 25,491,000,000.00 | 28,739,000,000.00 | 28,377,000,000.00 | N/A | 29,749,000,000.00 |
| Inventories | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 | N/A | 51,000,000.00 |
| Trade And Other Current Receivables | N/A | N/A | 2,463,000,000.00 | N/A | N/A | 3,367,000,000.00 | N/A | 3,876,000,000.00 | 4,951,000,000.00 | 5,910,000,000.00 | N/A | 4,690,000,000.00 |
| Current Tax Assets Current | N/A | N/A | 249,000,000.00 | N/A | N/A | 31,000,000.00 | N/A | 0.00 | 0.00 | 143,000,000.00 | N/A | 124,000,000.00 |
| Current Financial Assets At Fair Value Through Profit Or Loss Mandatorily Measured At Fair Value | N/A | N/A | 8,819,000,000.00 | N/A | N/A | 10,381,000,000.00 | N/A | 11,799,000,000.00 | 13,411,000,000.00 | 12,431,000,000.00 | 12,256,000,000.00 | 14,010,000,000.00 |
| Cash and cash equivalents | 533,000,000.00 | 3,552,000,000.00 | 7,260,000,000.00 | 9,477,000,000.00 | 8,729,000,000.00 | 8,957,000,000.00 | 9,071,000,000.00 | 9,816,000,000.00 | 10,377,000,000.00 | 9,893,000,000.00 | 12,288,000,000.00 | 10,874,000,000.00 |
| Balances With Banks | N/A | 2,884,000,000.00 | 5,054,000,000.00 | 6,908,000,000.00 | 8,542,000,000.00 | 8,661,000,000.00 | 8,512,000,000.00 | 8,810,000,000.00 | 9,082,000,000.00 | 9,299,000,000.00 | 11,583,000,000.00 | 10,240,000,000.00 |
| Shortterm Investments Classified As Cash Equivalents | N/A | 668,000,000.00 | 2,206,000,000.00 | 2,569,000,000.00 | 187,000,000.00 | 296,000,000.00 | 559,000,000.00 | 1,006,000,000.00 | 1,295,000,000.00 | 594,000,000.00 | 705,000,000.00 | 634,000,000.00 |
| Equity And Liabilities | N/A | N/A | 21,143,000,000.00 | N/A | N/A | 24,627,000,000.00 | N/A | 27,476,000,000.00 | 30,686,000,000.00 | 30,278,000,000.00 | N/A | 31,978,000,000.00 |
| Equity | 8,014,000,000.00 | 14,048,000,000.00 | 19,121,000,000.00 | 20,252,000,000.00 | 21,285,000,000.00 | 22,196,000,000.00 | N/A | 24,482,000,000.00 | 26,657,000,000.00 | 27,441,000,000.00 | N/A | 28,755,000,000.00 |
| Issued Capital | N/A | N/A | 66,000,000.00 | N/A | N/A | 66,000,000.00 | N/A | 66,000,000.00 | 66,000,000.00 | 66,000,000.00 | N/A | 66,000,000.00 |
| Retained Earnings | N/A | N/A | 7,107,000,000.00 | N/A | N/A | 10,020,000,000.00 | N/A | 12,243,000,000.00 | 14,299,000,000.00 | 14,968,000,000.00 | N/A | 16,165,000,000.00 |
| Share Premium | N/A | N/A | 11,894,000,000.00 | N/A | N/A | 12,029,000,000.00 | N/A | 12,063,000,000.00 | 12,141,000,000.00 | 12,309,000,000.00 | N/A | 12,412,000,000.00 |
| Other Reserves | N/A | N/A | 54,000,000.00 | N/A | N/A | 81,000,000.00 | N/A | 110,000,000.00 | 151,000,000.00 | 98,000,000.00 | N/A | 112,000,000.00 |
| Liabilities | N/A | N/A | 2,022,000,000.00 | N/A | N/A | 2,431,000,000.00 | N/A | 2,994,000,000.00 | 4,029,000,000.00 | 2,837,000,000.00 | N/A | 3,223,000,000.00 |
| Noncurrent Liabilities | N/A | N/A | 769,000,000.00 | N/A | N/A | 863,000,000.00 | N/A | 1,050,000,000.00 | 1,041,000,000.00 | 1,014,000,000.00 | N/A | 1,230,000,000.00 |
| Noncurrent Provisions | N/A | N/A | 4,000,000.00 | N/A | N/A | 13,000,000.00 | N/A | 7,000,000.00 | 7,000,000.00 | N/A | N/A | N/A |
| Noncurrent Deferred Income Including Noncurrent Contract Liabilities | N/A | N/A | N/A | N/A | N/A | 487,000,000.00 | N/A | N/A | 480,000,000.00 | 480,000,000.00 | 480,000,000.00 | 480,000,000.00 |
| Other Noncurrent Payables | N/A | N/A | 1,000,000.00 | N/A | N/A | 13,000,000.00 | N/A | 2,000,000.00 | 4,000,000.00 | 11,000,000.00 | 29,000,000.00 | 29,000,000.00 |
| Current Liabilities | N/A | N/A | 1,253,000,000.00 | N/A | N/A | 1,568,000,000.00 | N/A | 1,944,000,000.00 | 2,988,000,000.00 | 1,823,000,000.00 | N/A | 1,993,000,000.00 |
| Current Provisions | N/A | N/A | N/A | N/A | N/A | 0.00 | N/A | 6,000,000.00 | 6,000,000.00 | N/A | N/A | N/A |
| Current Deferred Income Including Current Contract Liabilities | N/A | N/A | N/A | N/A | N/A | 26,000,000.00 | N/A | N/A | 33,000,000.00 | 33,000,000.00 | 33,000,000.00 | 33,000,000.00 |
| Other Current Payables | N/A | N/A | 1,185,000,000.00 | N/A | N/A | 1,480,000,000.00 | N/A | 1,575,000,000.00 | 1,922,000,000.00 | 1,716,000,000.00 | 1,833,000,000.00 | 1,878,000,000.00 |
| Current Tax Liabilities Current | N/A | N/A | N/A | N/A | N/A | 0.00 | N/A | 257,000,000.00 | 948,000,000.00 | N/A | N/A | N/A |
| Line item in (dkk) | 01.01.2019/ 01.01.2020 |
01.01.2020/ 01.01.2021 |
01.01.2021/ 01.07.2021 |
01.01.2021/ 01.10.2021 |
01.01.2021/ 01.01.2022 |
01.04.2021/ 01.07.2021 |
01.07.2021/ 01.10.2021 |
01.01.2022/ 01.04.2022 |
01.01.2022/ 01.07.2022 |
01.01.2022/ 01.10.2022 |
01.01.2022/ 01.01.2023 |
01.04.2022/ 01.07.2022 |
01.07.2022/ 01.10.2022 |
01.01.2023/ 01.04.2023 |
01.01.2023/ 01.07.2023 |
01.04.2023/ 01.07.2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5,366,000,000.00 | 10,111,000,000.00 | 3,553,000,000.00 | 5,863,000,000.00 | 8,482,000,000.00 | 1,972,000,000.00 | 2,310,000,000.00 | N/A | 5,281,000,000.00 | 9,368,000,000.00 | 14,595,000,000.00 | 3,162,000,000.00 | 4,087,000,000.00 | N/A | 7,052,000,000.00 | 4,198,000,000.00 |
| Profit Loss From Operating Activities | 2,638,000,000.00 | 6,313,000,000.00 | 1,319,000,000.00 | 2,209,000,000.00 | 3,018,000,000.00 | 787,000,000.00 | 890,000,000.00 | N/A | 1,761,000,000.00 | 3,692,000,000.00 | 6,357,000,000.00 | 1,247,000,000.00 | 1,931,000,000.00 | N/A | 1,934,000,000.00 | 1,497,000,000.00 |
| Finance Income | 228,000,000.00 | 1,149,000,000.00 | 700,000,000.00 | 1,211,000,000.00 | 1,667,000,000.00 | 65,000,000.00 | 511,000,000.00 | N/A | 1,879,000,000.00 | 3,432,000,000.00 | 1,358,000,000.00 | 1,442,000,000.00 | 1,553,000,000.00 | N/A | 527,000,000.00 | 243,000,000.00 |
| Finance Costs | 7,000,000.00 | 1,558,000,000.00 | 173,000,000.00 | 403,000,000.00 | 702,000,000.00 | 430,000,000.00 | 230,000,000.00 | N/A | 539,000,000.00 | 751,000,000.00 | 680,000,000.00 | 200,000,000.00 | 212,000,000.00 | N/A | 452,000,000.00 | 17,000,000.00 |
| Profit Loss Before Tax | 2,859,000,000.00 | 5,904,000,000.00 | 1,846,000,000.00 | 3,017,000,000.00 | 3,983,000,000.00 | 422,000,000.00 | 1,171,000,000.00 | N/A | 3,101,000,000.00 | 6,373,000,000.00 | 7,035,000,000.00 | 2,489,000,000.00 | 3,272,000,000.00 | N/A | 2,009,000,000.00 | 1,723,000,000.00 |
| Income Tax Expense Continuing Operations | 693,000,000.00 | 1,146,000,000.00 | 444,000,000.00 | 725,000,000.00 | 975,000,000.00 | 116,000,000.00 | 281,000,000.00 | N/A | 745,000,000.00 | 1,435,000,000.00 | 1,513,000,000.00 | 598,000,000.00 | 690,000,000.00 | N/A | 426,000,000.00 | 366,000,000.00 |
| Profit (loss) | 2,166,000,000.00 | 4,758,000,000.00 | 1,402,000,000.00 | 2,292,000,000.00 | 3,008,000,000.00 | 306,000,000.00 | 890,000,000.00 | 465,000,000.00 | 2,356,000,000.00 | 4,938,000,000.00 | 5,522,000,000.00 | 1,891,000,000.00 | 2,582,000,000.00 | 226,000,000.00 | 1,583,000,000.00 | 1,357,000,000.00 |
| Line item in (dkk) | 01.01.2019 | 01.01.2020 | 01.01.2021 | 01.07.2021 | 01.10.2021 | 01.01.2022 | 01.04.2022 | 01.07.2022 | 01.10.2022 | 01.01.2023 | 01.04.2023 | 01.07.2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profit (loss) | N/A | 2,166,000,000.00 | 4,758,000,000.00 | 306,000,000.00 | 890,000,000.00 | 3,008,000,000.00 | 465,000,000.00 | 1,891,000,000.00 | 2,582,000,000.00 | 5,522,000,000.00 | 226,000,000.00 | 1,357,000,000.00 |
| Other Adjustments For Noncash Items | N/A | 291,000,000.00 | 459,000,000.00 | 227,000,000.00 | 376,000,000.00 | 526,000,000.00 | N/A | 347,000,000.00 | 574,000,000.00 | 801,000,000.00 | N/A | 423,000,000.00 |
| Cash Flows From Used In Operations | N/A | 1,711,000,000.00 | 7,759,000,000.00 | 1,441,000,000.00 | 1,829,000,000.00 | 2,774,000,000.00 | N/A | 1,929,000,000.00 | 3,812,000,000.00 | 5,228,000,000.00 | N/A | 3,698,000,000.00 |
| Interest Paid Classified As Operating Activities | N/A | N/A | N/A | N/A | 0.00 | N/A | N/A | 1,000,000.00 | 1,000,000.00 | N/A | N/A | 0.00 |
| Interest Received Classified As Operating Activities | N/A | 111,000,000.00 | 170,000,000.00 | 107,000,000.00 | 169,000,000.00 | 208,000,000.00 | N/A | 80,000,000.00 | 169,000,000.00 | 283,000,000.00 | N/A | 384,000,000.00 |
| Cash Flows From Used In Operating Activities | N/A | 1,326,000,000.00 | 6,433,000,000.00 | 1,540,000,000.00 | 1,987,000,000.00 | 2,228,000,000.00 | N/A | 1,546,000,000.00 | 3,514,000,000.00 | 3,912,000,000.00 | N/A | 3,671,000,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 79,000,000.00 | 307,000,000.00 | 107,000,000.00 | 184,000,000.00 | 252,000,000.00 | N/A | 125,000,000.00 | 207,000,000.00 | 317,000,000.00 | N/A | 201,000,000.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | N/A | 32,000,000.00 | 0.00 | N/A | N/A | 0.00 | N/A | 0.00 | N/A | N/A | N/A | 10,000,000.00 |
| Cash Flows From Used In Investing Activities | N/A | -1,983,000,000.00 | -2,351,000,000.00 | 966,000,000.00 | -655,000,000.00 | -961,000,000.00 | N/A | -1,243,000,000.00 | -2,625,000,000.00 | -2,761,000,000.00 | N/A | -1,848,000,000.00 |
| Proceeds From Issuing Shares | N/A | 3,873,000,000.00 | 0.00 | N/A | N/A | 0.00 | N/A | N/A | N/A | N/A | N/A | N/A |
| Payments To Acquire Or Redeem Entitys Shares | N/A | 0.00 | 0.00 | 437,000,000.00 | 447,000,000.00 | 447,000,000.00 | N/A | 211,000,000.00 | 908,000,000.00 | 908,000,000.00 | N/A | 564,000,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 31,000,000.00 | 44,000,000.00 | 29,000,000.00 | 50,000,000.00 | 58,000,000.00 | N/A | 30,000,000.00 | 47,000,000.00 | 73,000,000.00 | N/A | 50,000,000.00 |
| Cash Flows From Used In Financing Activities | N/A | 3,660,000,000.00 | 71,000,000.00 | -460,000,000.00 | -436,000,000.00 | -420,000,000.00 | N/A | -278,000,000.00 | -920,000,000.00 | -789,000,000.00 | N/A | -604,000,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | N/A | 3,003,000,000.00 | 4,153,000,000.00 | 2,046,000,000.00 | N/A | 847,000,000.00 | N/A | 25,000,000.00 | N/A | 362,000,000.00 | N/A | N/A |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | 16,000,000.00 | -445,000,000.00 | 171,000,000.00 | 573,000,000.00 | 850,000,000.00 | N/A | 834,000,000.00 | 1,451,000,000.00 | 574,000,000.00 | N/A | -238,000,000.00 |
| Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | N/A | N/A | N/A | N/A | 896,000,000.00 | N/A | -144,000,000.00 | 25,000,000.00 | -31,000,000.00 | N/A | 2,611,000,000.00 | 1,219,000,000.00 |
| Cash and cash equivalents | 533,000,000.00 | 3,552,000,000.00 | 7,260,000,000.00 | 9,477,000,000.00 | 8,729,000,000.00 | 8,957,000,000.00 | 9,071,000,000.00 | 9,816,000,000.00 | 10,377,000,000.00 | 9,893,000,000.00 | 12,288,000,000.00 | 10,874,000,000.00 |
Please note that some sums might not add up.
DK0010272202
LEI529900MTJPDPE4MHJ122
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryOMX Copenhagen 20
Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.